Platelet‐activating factor inhibits proteoglycan synthesis and enhances neutrophil‐mediated proteoglycan degradation in cartilage explants

I. C. Kowanko, E. J. Bates, A. Ferrante

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective. Platelet‐activating factor (PAF), which stimulates the release of tissue‐destructive enzymes and reactive oxygen metabolites from neutrophils, was investigated for its role in neutrophil‐mediated cartilage breakdown. Methods. Bovine cartilage explants were incubated with or without human neutrophils, PAF, and other reagents. Cartilage damage was measured as either proteoglycan degradation (percent release of 35S‐labeled proteoglycan from 35S‐labeled cartilage) or inhibition of proteoglycan synthesis (rate of incorporation of 35S into proteoglycan). Results. PAF increased neutrophil‐mediated proteoglycan degradation in the 2–20 μM range. Three specific PAF‐receptor antagonists, WEB2086, CV3988, and CV6209, reversed this effect of PAF. These antagonists also reduced the enhancement of neutrophilmediated cartilage damage caused by granulocyte–macrophage colony‐stimulating factor (GM‐CSF) and tumor necrosis factor α (TNFα). The results suggest that there may be a positive feedback mechanism whereby cytokine‐primed neutrophils produce PAF, which amplifies the release of other tissue‐damaging substances from neutrophils. In the absence of neutrophils, PAF (2–20 μM) inhibited the synthesis of proteoglycan by bovine cartilage. Neutrophils also inhibit proteoglycan synthesis, but PAF probably is not involved in this effect of neutrophils because the PAF receptor antagonists had no consistent effect. Conclusion. PAF increases neutrophil‐mediated cartilage proteoglycan degradation in vitro. GM‐CSF and TNFα enhancement of neutrophil damage to cartilage is partly due to PAF. PAF alone inhibits cartilage proteoglycan synthesis.

LanguageEnglish
Pages918-925
Number of pages8
JournalArthritis & Rheumatism
Volume35
Issue number8
DOIs
Publication statusPublished - 1 Jan 1992

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

@article{1f989ca91d6243069015b49652a102ed,
title = "Platelet‐activating factor inhibits proteoglycan synthesis and enhances neutrophil‐mediated proteoglycan degradation in cartilage explants",
abstract = "Objective. Platelet‐activating factor (PAF), which stimulates the release of tissue‐destructive enzymes and reactive oxygen metabolites from neutrophils, was investigated for its role in neutrophil‐mediated cartilage breakdown. Methods. Bovine cartilage explants were incubated with or without human neutrophils, PAF, and other reagents. Cartilage damage was measured as either proteoglycan degradation (percent release of 35S‐labeled proteoglycan from 35S‐labeled cartilage) or inhibition of proteoglycan synthesis (rate of incorporation of 35S into proteoglycan). Results. PAF increased neutrophil‐mediated proteoglycan degradation in the 2–20 μM range. Three specific PAF‐receptor antagonists, WEB2086, CV3988, and CV6209, reversed this effect of PAF. These antagonists also reduced the enhancement of neutrophilmediated cartilage damage caused by granulocyte–macrophage colony‐stimulating factor (GM‐CSF) and tumor necrosis factor α (TNFα). The results suggest that there may be a positive feedback mechanism whereby cytokine‐primed neutrophils produce PAF, which amplifies the release of other tissue‐damaging substances from neutrophils. In the absence of neutrophils, PAF (2–20 μM) inhibited the synthesis of proteoglycan by bovine cartilage. Neutrophils also inhibit proteoglycan synthesis, but PAF probably is not involved in this effect of neutrophils because the PAF receptor antagonists had no consistent effect. Conclusion. PAF increases neutrophil‐mediated cartilage proteoglycan degradation in vitro. GM‐CSF and TNFα enhancement of neutrophil damage to cartilage is partly due to PAF. PAF alone inhibits cartilage proteoglycan synthesis.",
author = "Kowanko, {I. C.} and Bates, {E. J.} and A. Ferrante",
year = "1992",
month = "1",
day = "1",
doi = "10.1002/art.1780350811",
language = "English",
volume = "35",
pages = "918--925",
journal = "Arthritis and rheumatism",
issn = "0004-3591",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

Platelet‐activating factor inhibits proteoglycan synthesis and enhances neutrophil‐mediated proteoglycan degradation in cartilage explants. / Kowanko, I. C.; Bates, E. J.; Ferrante, A.

In: Arthritis & Rheumatism, Vol. 35, No. 8, 01.01.1992, p. 918-925.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Platelet‐activating factor inhibits proteoglycan synthesis and enhances neutrophil‐mediated proteoglycan degradation in cartilage explants

AU - Kowanko, I. C.

AU - Bates, E. J.

AU - Ferrante, A.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Objective. Platelet‐activating factor (PAF), which stimulates the release of tissue‐destructive enzymes and reactive oxygen metabolites from neutrophils, was investigated for its role in neutrophil‐mediated cartilage breakdown. Methods. Bovine cartilage explants were incubated with or without human neutrophils, PAF, and other reagents. Cartilage damage was measured as either proteoglycan degradation (percent release of 35S‐labeled proteoglycan from 35S‐labeled cartilage) or inhibition of proteoglycan synthesis (rate of incorporation of 35S into proteoglycan). Results. PAF increased neutrophil‐mediated proteoglycan degradation in the 2–20 μM range. Three specific PAF‐receptor antagonists, WEB2086, CV3988, and CV6209, reversed this effect of PAF. These antagonists also reduced the enhancement of neutrophilmediated cartilage damage caused by granulocyte–macrophage colony‐stimulating factor (GM‐CSF) and tumor necrosis factor α (TNFα). The results suggest that there may be a positive feedback mechanism whereby cytokine‐primed neutrophils produce PAF, which amplifies the release of other tissue‐damaging substances from neutrophils. In the absence of neutrophils, PAF (2–20 μM) inhibited the synthesis of proteoglycan by bovine cartilage. Neutrophils also inhibit proteoglycan synthesis, but PAF probably is not involved in this effect of neutrophils because the PAF receptor antagonists had no consistent effect. Conclusion. PAF increases neutrophil‐mediated cartilage proteoglycan degradation in vitro. GM‐CSF and TNFα enhancement of neutrophil damage to cartilage is partly due to PAF. PAF alone inhibits cartilage proteoglycan synthesis.

AB - Objective. Platelet‐activating factor (PAF), which stimulates the release of tissue‐destructive enzymes and reactive oxygen metabolites from neutrophils, was investigated for its role in neutrophil‐mediated cartilage breakdown. Methods. Bovine cartilage explants were incubated with or without human neutrophils, PAF, and other reagents. Cartilage damage was measured as either proteoglycan degradation (percent release of 35S‐labeled proteoglycan from 35S‐labeled cartilage) or inhibition of proteoglycan synthesis (rate of incorporation of 35S into proteoglycan). Results. PAF increased neutrophil‐mediated proteoglycan degradation in the 2–20 μM range. Three specific PAF‐receptor antagonists, WEB2086, CV3988, and CV6209, reversed this effect of PAF. These antagonists also reduced the enhancement of neutrophilmediated cartilage damage caused by granulocyte–macrophage colony‐stimulating factor (GM‐CSF) and tumor necrosis factor α (TNFα). The results suggest that there may be a positive feedback mechanism whereby cytokine‐primed neutrophils produce PAF, which amplifies the release of other tissue‐damaging substances from neutrophils. In the absence of neutrophils, PAF (2–20 μM) inhibited the synthesis of proteoglycan by bovine cartilage. Neutrophils also inhibit proteoglycan synthesis, but PAF probably is not involved in this effect of neutrophils because the PAF receptor antagonists had no consistent effect. Conclusion. PAF increases neutrophil‐mediated cartilage proteoglycan degradation in vitro. GM‐CSF and TNFα enhancement of neutrophil damage to cartilage is partly due to PAF. PAF alone inhibits cartilage proteoglycan synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0026708546&partnerID=8YFLogxK

U2 - 10.1002/art.1780350811

DO - 10.1002/art.1780350811

M3 - Article

VL - 35

SP - 918

EP - 925

JO - Arthritis and rheumatism

T2 - Arthritis and rheumatism

JF - Arthritis and rheumatism

SN - 0004-3591

IS - 8

ER -